Quidel Corporation (QDEL) stock is lower by 11.20% over the past week and gets a Bearish rating from InvestorsObserver's Sentiment Indicator.
What is Stock Sentiment?
In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company.
Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish.
InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion.
For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.
What's Happening With QDEL Stock Today?
Quidel Corporation (QDEL) stock is trading at $152.85 as of 12:21 PM on Wednesday, Mar 3, a decline of -$8.44, or -5.23% from the previous closing price of $161.29. The stock has traded between $149.50 and $162.37 so far today. Volume today is less active than usual. So far 614,593 shares have traded compared to average volume of 888,731 shares.
To screen for more stocks like Quidel Corporation click here.
More About Quidel Corporation
Quidel Corp is engaged in the development, manufacturing, and marketing of rapid diagnostic testing solutions. It is separated into four product categories: Rapid immunoassays, Cardiac immunoassays, Specialized diagnostic solutions and Molecular diagnostic solutions. Rapid immunoassay and Cardiac immunoassay tests for use in physician offices, hospital laboratories and emergency departments, retail clinics, eye health settings, pharmacies and other urgent care sites, Specialized diagnostic solutions, including direct fluorescent assays and culture-based tests, and Molecular diagnostic tests across a number of hospitals, moderately complex physician offices, laboratories and other segments. The company generates a majority of its revenue from the rapid immunoassays.
Click Here to get the full Stock Score Report on Quidel Corporation (QDEL) Stock.
